Project Grant DP2AG082342
Award Date
9/30/22
Completion Date
8/31/25
Dollars Obligated
$3M
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) will provide $2,114,698 to the University of North Texas Health Science Center at Fort Worth to conduct research on the impact of sex and hippocampal angiotensin II on Alzheimer's disease. The research will seek to elucidate the mechanisms involved in the observed sex differences in Alzheimer's disease risk, with a focus on the interaction between sex chromosomes, sex hormones,...
The National Institute on Aging (NIA) awarded a $1,858,368 Project Grant through the Aging Research program (CFDA 93.866) to Brigham & Women's Hospital Inc. in Boston, Massachusetts. The grant, titled "SORL 1-RETROMER BIOLOGY IN THE PATHOGENESIS OF ALZHEIMERS DISEASE", is intended to support comprehensive scientific investigations into the biological mechanisms underlying Alzheimer's disease. The 3-year grant, running from September 30, 2024 to August 31, 2027, will fund research...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,389,865.00 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop "smart" chemiluminescence probes for high-throughput imaging of amyloid beta in preclinical Alzheimer's disease (AD) research. The goal is to create an accessible, sensitive, and cost-effective optical imaging method to accelerate preclinical AD drug development....
This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) is for $498,748 to the University of Massachusetts Medical School (UMass Medical) to elucidate the mechanisms by which MS4A genes regulate neurodegeneration in Alzheimer's disease and related disorders. The project aims to examine the effects of deleting other MS4A gene family members, beyond just MS4A6C, on neurodegenerative phenotypes, as well as explore the underlying mechanisms by which...
This federal Project Grant awarded by the National Institute on Aging under CFDA 93.866 (Aging Research) aims to examine the role of specific phenotypes, such as sex/gender, APOE4 status, and polygenic hazard scores, on response to drug or lifestyle interventions in existing Alzheimer's disease clinical trials datasets. The $3,281,385 grant, awarded on September 1, 2024, will leverage data from 14,602 participants in 30 years of Alzheimer's clinical trials to analyze the impact of these...
The National Institutes of Health's National Institute on Aging awarded a $5,063,226 Project Grant to Brigham and Women's Hospital Inc. under the Aging Research program (CFDA 93.866) for the period of September 1, 2022 through August 31, 2025. The grant funds research to analyze the functional role of glial cells in tauopathy and Alzheimer's disease. Researchers will use genetic approaches in Drosophila to identify glial proteins and pathways that influence tau neurotoxicity in aging adult fly...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), provides $2,340,172.00 in funding to develop novel small molecule inhibitors targeting HDAC11 as potential treatments for Alzheimer's disease (AD). The project aims to explore structure-activity relationships (SAR) of a leading scaffold to create a new generation of HDAC11-selective inhibitors, which will then be...
This $3.5 million project grant from the National Institutes of Health's National Institute on Aging will fund research into sex differences related to epigenetic parent-of-origin effects and Alzheimer's disease. The Regents of the University of California, San Francisco will investigate how the maternal versus paternal X chromosome impacts neural vulnerability to Alzheimer's-related deficits in mouse models and primary neurons. The researchers hypothesize that imprinting or silencing of genes...
This federal Project Grant award of $2,173,794 from the National Institute on Aging's Aging Research program (CFDA 93.866) supports research to explore the potential of adult hippocampal neurogenesis (AHN) and brain-derived neurotrophic factor (BDNF) as therapeutic strategies for treating cognitive decline in Alzheimer's disease (AD). The primary awardee, The General Hospital Corporation (doing business as Massachusetts General Hospital), will lead this 3-year project to: Investigate the...
This federal Project Grant award in the amount of $2,201,136 was provided by the National Institute on Aging (NIA) under the NIA Aging Research program (CFDA 93.866) to The Trustees of Columbia University in the City of New York. The award aims to improve the understanding of Alzheimer's disease (AD) and related dementias (ADRD) by developing a comprehensive view of their genetic architecture. The project will leverage large-scale biobanks and electronic medical records to systematically study...